n.a. (CLTX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Calyxt Announces Upsizing And Pricing Of Follow-On Offering

Calyxt Announces Upsizing And Pricing Of Follow-On Offering
Celsus Therapeutics And Volution Immuno Pharmaceuticals Announce Completion Of Acquisition And Formation Of Complement C5 Inhibitor Company Akari Therapeutics Plc

Celsus Therapeutics And Volution Immuno Pharmaceuticals Announce Completion Of Acquisition And Formation Of Complement C5 Inhibitor Company Akari Therapeutics Plc

Calyxt Announces Upsizing And Pricing Of Follow-On Offering

Cellectis S.A.

Business Wire

Celsus Therapeutics And Volution Immuno Pharmaceuticals Announce Completion Of Acquisition And Formation Of Complement C5 Inhibitor Company Akari Therapeutics Plc

GlobeNewswire

Celsus Therapeutics (CLTX) Stock Hits One-Year Low Following Disappointing Trial Results

Shares of Celsus Therapeutics (CLTX) plunged more to a 52-week low in morning trading Tuesday after the biotech company announced the results of its dermatitis treatment in a mid-stage trial.

Andrew Meola

Celsus Therapeutics Announces That The Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

MRX-6 Cream Did Not Demonstrate Separation From Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment

GlobeNewswire

Celsus Therapeutics Completes Enrollment Of Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis

Topline Data From Double-Blind Portion of Trial Expected by End of February, 2015

GlobeNewswire

Celsus Therapeutics Announces FDA Allowance Of IND For Clinical Development Of MRX-6 Cream In Atopic Dermatitis

Phase II Dose Ranging Clinical Trial in Atopic Dermatitis Expected to Begin in First Quarter of 2015

GlobeNewswire

Celsus Therapeutics Announces Upcoming Presentation At Oppenheimer 25th Annual Healthcare Conference

GlobeNewswire

Celsus Therapeutics Plc Announces First Patient Enrolled In Phase II Trial Of MRX-6 In Pediatric Atopic Dermatitis

Results Expected in Fourth Quarter of 2014

GlobeNewswire
Get the Investing Edge.
Join Jim Cramer's Members-Only Investing Club
Become an Action Alerts PLUS member to learn from the pros how to invest wisely and build a customized portolio of blue chip stocks.
LEARN MORE
Uncover New Investment Opportunities With Our Team of Experts
Jim Cramer and his army of Wall Street pros serve up new trading ideas and in-depth market analysis every day.
LEARN MORE

Watchlist